Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Menu
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

OKC firm seeking to boost effectiveness of antibiotics receives investment

Get in Touch

From Staff Reports
Copyright © 2015 The Oklahoma Publishing Co.

i2E Inc. and Accele Venture Partners recently closed a $600,000 follow-on investment in Synereca Pharmaceuticals, a portfolio company of Accele Biopharma, an Oklahoma City-based biotechnology accelerator.

With the most recent investment, Synereca has now received $2.5 million in funding to support its development of compounds that address the growing problem of bacterial resistance to current antibiotics.

Synereca’s lead program is designed to restore or increase the effectiveness of existing antibiotics that have been compromised by drug-resistant bacteria. Preclinical results have shown that combining Synereca’s compounds with current antibiotics restores and enhances their activity against highly resistant pathogens that cause difficult-to-treat bacterial infections.

Synereca is based in Oklahoma City, and has laboratories in Oklahoma City and North Carolina.

The latest investment round was led by Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, the Oklahoma Seed Capital Fund, managed by i2E Inc., and other existing investors.

“Synereca’s approach — potentiating the activity of existing classes of antibiotics — has demonstrated compelling preclinical results,” said Clayton Duncan, the company’s CEO. “Gram-Negative hospital-acquired infections are an important clinical need for hundreds of thousands of patients, and this capital enables Synereca to select its first Investigational New Drug candidate.”

The Oklahoma Seed Capital Fund is a state-appropriated fund managed by i2E through a contract with the Oklahoma Center for the Advancement of Science and Technology.

Located in the University Research Park in Oklahoma City, Accele Biopharma was created as a business accelerator to enable bioscience startups to develop groundbreaking science from the laboratory to the proof of concept stage and beyond.

Accele Venture Partners LP is a limited partnership formed to invest, together with established institutional life science investors, in the initial funding of life science companies selected and managed by Accele Biopharma Inc.

Read the full story at newsok.com

Author

  • admin admin

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E